FDA Approves Abbott's Novel Dissolvable Stent Therapy for Peripheral Artery Disease
Abbott's Esprit BTK System was shown to significantly reduce risk of ischemic events in patients with PAD versus angioplasty over 1 year.
Read More
Glomerulonephritis Patients Face High Risk of Recurrence After Kidney Transplant
A single-center assessment showed patients with glomerulonephritis may face a heightened risk of primary disease recurrence up to 1 year after transplant.
2024 State of the Air: Record Highs in US Particle Pollution, with John Balmes, MD
Balmes discusses the latest annual State of the Air Report, which shows that 131 million Americans are living in areas with failing air quality grades.
FDA Issues CRL to Abeona for Potential RDEB Cell Therapy
Abeona's pz-cel is up for indicated use to treat patients with recessive dystrophic epidermolysis bullosa.
Longer Emergency Department Boarding Increases Risk of Patient Discrimination, Dissatisfaction
Data presented at ACP 2024 shows non-White patients may be particularly subjected to more risk of discrimination in their care when ED boarding extends past 24 hours.
Pre-Visit Planning Could Significantly Improve Pneumococcal Vaccination Rates
A study presented at ACP 2024 shows benefit with preparing to offer pneumococcal vaccination to incoming patients in an ambulatory setting.
Budesonide Maintains IgA Nephropathy Kidney Failure Reduction, Quality of Life at 2 Years
New phase 3 findings show daily oral budesonide reduces eGFR decline while maintaining patient quality of life over 2 years.
9 Biosimilars for Intravitreal nAMD, DME Treatment
A number of biosimilar options to treat the common retina diseases are in development globally. Here’s a highlight of 9 with supporting late-stage data.
Improving Donor Lung Allocation with Kenneth McCurry, MD & Maryam Valapour, MD, MPP
Cleveland Clinic lung transplant experts rejoin Lungcast to discuss optimization of the lung allocation system to continue reducing waitlist times and patient mortality.
COPD, IPF Linked to More Severe COVID-19 Outcomes, Mortality Risk
New data show COPD and IPF, among other interstitial lung diseases, are more significantly associated with poor 30-day outcomes from COVID-19 than asthma.
FDA Issues Warning for Topical Analgesics with High Levels of Lidocaine
The FDA identified high concentration of lidocaine across marketed, over-the-counter topical products from 6 different companies.
SGLT2 Inhibitors Could Play a Role in Treating Gout
A new review considers how SGLT2 inhibitors like dapagliflozin and empagliflozin have been shown to clinically improve gout while reducing its cardiometabolic and renal comorbidities.
Periprosthetic Joint Infections Linked to Increased Mortality in Rheumatoid Arthritis Patients
Despite being a rare occurrence, the infection was linked to deaths in 1 in 5 observed patients.
COPD May Be Causally Linked to Rheumatoid Arthritis, Osteoarthritis
A new study suggests patients with either rheumatoid arthritis or osteoarthritis may be at a higher genetic susceptibility to develop COPD.
Benzbromarone Provides More Rapid Gout Benefit than Febuxostat
A comparison of the urate-lowering therapies shows discrepancies in short- and long-term use outcomes.
ARDS Due to COVID-19 Linked to Heart Damage Risk
New data from NIH investigators show acute respiratory distress syndrome from COVID-19 infection may trigger heart inflammation in patients.
Switching Adalimumab, Upadacitinib May Provide Long-Term RA Benefit
New 5 year data from the phase 3 SELECT-COMPARE trial suggest a patient with RA not responding to adalimumab or upadacitinib may fare better switching to the other.
Children with Eczema Struggle More with Comorbid ADHD Symptoms
New data suggest children with atopic dermatitis and comorbid ADHD are nearly 3 times more likely to struggle with memory compared to those with just ADHD.
Addressing HS Risks at the Genetic Level, with Kai Li, BSc
Data show significant maternal and fetal risks in cases when pregnant women are diagnosed with hidradenitis suppurativa. A researcher discusses opportunities to learn more.
Analysis: Pediatric Isotretinoin Use Not Linked to Shorter Adult Height
Isotretinoin was actually linked to a taller adult height among those who took it to treat acne in childhood versus doxycycline, in a new study.
Pediatric Contact Dermatitis Allergens Vary by Age, Sex, Race
New data show sensitization among children with allergic contact dermatitis may be significantly influenced by their age and gender, among other demographic details.
Andrew F. Alexis, MD, MPH: ADORING Trials, Tapinarof Cream, and Improving Skin of Color Research Representation
Alexis discusses clinical and demographic hurdles in treating skin of color for conditions like atopic dermatitis, and the potential of research like that being done in tapinarof cream 1%.
Building a Psoriasis Knockout Regimen Around Risankizumab, with Andrew Blauvelt, MD, MBA
Blauvelt discusses the future research of higher-dose risankizumab for patients with psoriasis—and why it may be "disruptive in the treatment space."
Children with Atopic Dermatitis May Be Shorter in Height
New global data suggest children with moderate to severe atopic dermatitis may experience stunted growth due to the effect of their disease on sleep, as well as use of certain therapies.
Joel Gelfand, MD, MSCE: Phototherapy Utility in Psoriasis
Gelfand discusses the convenience of phototherapy, and how its efficacy may complement biologic regimens in patients with psoriasis.
Pediatric Hidradenitis Suppurativa Severity not Linked to Obesity
New data from the Mayo Clinic show high BMI does not correlate with severe hidradenitis suppurativa in affected children and adolescents.
Johnson & Johnson Submits Guselkumab Application to FDA for Ulcerative Colitits
The submission could grant guselkumab its third indication, after being approved by the FDA for psoriasis and psoriatic arthritis.
Risankizumab and the KNOCKOUT Study, with Andrew Blauvelt, MD, MBA
Blauvelt discusses the impetus for his phase 2 trial looking at the ability to mitigate pivotal psoriasis memory T cells with risankizumab.
Tapinarof Cream Significantly Improves Atopic Dermatitis Regardless of Skin Color
In a phase 3 trial that featured approximately half of participants with skin of color, tapinarof cream 1.0% provided consistent benefit for patients identified as White, Black, or Asian.
Brian Kim, MD: Pushing Dermatology Forward and Alys Pharmaceuticals
Kim discusses the state of dermatology innovation and applied care, as well as his involvement in a new company in the space.